Clene Inc. to Showcase Innovations at H.C. Wainwright Conference
Clene Inc. (Nasdaq: CLNN), along with its subsidiary Clene Nanomedicine Inc., is preparing for an exciting opportunity at the H.C. Wainwright 26th Annual Global Investment Conference. This event marks a significant moment for Clene, a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and preserving neuronal function in the fight against neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
Details of the Conference Presentation
The management team has confirmed their participation in this important conference, set to take place on September 9, 2024. Clene's presentation will begin at 7:00 am EST and will be delivered virtually, allowing a broader audience to engage. Furthermore, the management team will be available for one-on-one meetings with investors, providing an opportunity for direct discussions about the company's innovative strategies and projects.
How to Access the Presentation
A webcast of the presentation will be available in the “Events” section of Clene's website. Interested viewers are encouraged to register online to ensure they can access the valuable insights that will be shared during the session.
Exploring Clene's Mission and Innovations
At its foundation, Clene Inc. (Nasdaq: CLNN) is committed to making notable advancements in the biopharmaceutical sector. Its flagship product, CNM-Au8®, is an investigational therapy recognized for its unique method of enhancing the functions of central nervous system cells. This innovative treatment targets mitochondrial functions while alleviating oxidative stress, which are key factors in many neurodegenerative diseases.
The Significance of Mitochondrial Health
Mitochondrial health is essential for the survival and functionality of cells, particularly neurons that are highly susceptible to degeneration. Clene's commitment to enhancing mitochondrial function signifies a groundbreaking approach to treating conditions that severely affect quality of life.
Company's Research Focus and Commitment
Based in Salt Lake City, Utah, Clene emphasizes its dedication through extensive research and development efforts in Maryland. Their innovative initiatives aim not only to meet current medical needs but also to lay the groundwork for future breakthroughs in the treatment of neurodegenerative disorders.
Stay Informed About Clene
For those interested in keeping up with Clene's progress and developments, the company maintains a strong online presence. You can follow them on social media platforms such as X (formerly Twitter) and LinkedIn, where they provide updates on their ongoing research and company news.
Frequently Asked Questions
What is the main focus of Clene Inc.?
Clene Inc. is dedicated to improving mitochondrial health and safeguarding neuronal function to treat neurodegenerative diseases like ALS and MS.
When will Clene's presentation at the conference take place?
The presentation is set for September 9, 2024, at 7:00 am EST.
How can I access Clene's conference presentation?
A webcast of the presentation will be available on Clene's website in the “Events” section, and registration is open online for those interested.
What is CNM-Au8®?
CNM-Au8® is an investigational therapy aimed at enhancing the survival and function of central nervous system cells by improving mitochondrial function and decreasing oxidative stress.
How can I contact Clene for media or investor inquiries?
For media inquiries, please reach out to Ignacio Guerrero-Ros at Ignacio.guerrero-ros@russopartnersllc.com or David Schull at David.schull@russopartnersllc.com. For investor inquiries, contact Kevin Gardner at kgardner@lifesciadvisors.com.
